Institut De Recherches Internationales Servier (i.r.i.s.)
Clinical trials sponsored by Institut De Recherches Internationales Servier (i.r.i.s.), explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Liver study checks how vorasidenib behaves in sick patients Results expected Nov 2026 (estimated)
- New pill shows promise for tough leukemias in early trial Results expected Dec 2026 (estimated)
-
Cancer drug may weaken birth control: new study checks
Knowledge-focused CompletedThis study looked at whether the cancer drug vorasidenib changes how a common birth control pill works in 28 healthy women. Participants took the birth control pill alone, then later took it together with vorasidenib. Researchers measured drug levels in the blood and watched for …
Phase 1 • Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Cancer drug vorasidenib put to the test: will it clash with common meds?
Knowledge-focused CompletedThis study in 28 healthy adults checks whether the experimental cancer drug vorasidenib changes how the body processes several common medications, including pain relievers, sedatives, and cholesterol drugs. Participants take the other drugs alone and then again with vorasidenib t…
Phase 1 • Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC